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Background. Personalised medicine in oncology needs standardised immunological assays. Flow cytometry (FCM) methods represent
an essential tool for immunomonitoring, and their harmonisation is crucial to obtain comparable data in multicentre clinical trials.
The objective of this study was to design a harmonisation workflow able to address the most effective issues contributing to intra-
and interoperator variabilities in a multicentre project. Methods. The Italian National Institute of Health (Istituto Superiore di
Sanità, ISS) managed a multiparametric flow cytometric panel harmonisation among thirteen operators belonging to five clinical
and research centres of Lazio region (Italy). The panel was based on a backbone mixture of dried antibodies (anti-CD3, anti-
CD4, anti-CD8, anti-CD45RA, and anti-CCR7) to detect naïve/memory T cells, recognised as potential prognostic/predictive
immunological biomarkers in cancer immunotherapies. The coordinating centre distributed frozen peripheral blood mononuclear
cells (PBMCs) and fresh whole blood (WB) samples from healthy donors, reagents, and Standard Operating Procedures (SOPs) to
participants who performed experiments by their own equipment, in order to mimic a real-life scenario. Operators returned raw
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and locally analysed data to ISS for central analysis and statistical elaboration. Results. Harmonised and reproducible results were
obtained by sharing experimental set-up and procedures along with centralising data analysis, leading to a reduction of cross-
centre variability for naïve/memory subset frequencies particularly in the whole blood setting. Conclusion. Our experimental and
analytical working process proved to be suitable for the harmonisation of FCM assays in a multicentre setting, where high-quality
data are required to evaluate potential immunological markers, which may contribute to select better therapeutic options.
1. Introduction
Immunomonitoring has become increasingly relevant in the
immunooncology field for the identification of potential
prognostic/predictive immune biomarkers and a better under-
standing of their underlying mechanisms of action, leading to
improved personalised treatments.
FCM is a powerful technology commonly used to dissect
the immune phenotype due to its unique ability to measure
quantitatively and simultaneously large numbers of single
cells by multiple markers. However, given the complexity of
polychromatic assays currently used in immunotherapy
studies, a harmonisation process is crucial to guarantee
reproducibility of data among laboratories, especially in
multicentre trials [1–3].
In most cases, monitoring of patients’ response is con-
ducted over an extended time lapse, from the pretreatment
phase to the follow-up period, and in this context, assay
repeatability must be considered mandatory. For this rea-
son, FCM assays need to meet specific analytical method
validation especially in settings requiring good laboratory/-
clinical practice (GLP/GCP) compliance. According to the
Food and Drug Administration (FDA), validation is rea-
lised to confirm that the method is fit for its intended use
(“fit-for-purpose, FFP”), satisfying specific criteria with
respect to stability, accuracy, precision, specificity, detection
limit, linearity, ruggedness, and robustness [4–7]. Neverthe-
less, continuous improvement of best practices and evolution
of immune cell phenotyping requires periodic upgrading of
FCM-based methods and technology [8].
Currently, the only existing guidelines for validating flow
cytometric assays are gathered from guidance documents
and recommendations published in specific journals [9, 10].
So far, several harmonisation and standardisation programs
have been promoted and activated, e.g., by the Human
Immune Phenotyping Consortium (HIPC) [11], the EuroFlow
Consortium [3, 12], and the ONE Study Consortium [13].
In clinical cancer studies, due to the feasibility and repro-
ducibility of blood compared to tumour tissue sampling,
immune phenotyping of peripheral blood leukocyte subpop-
ulations is considered as a valuable approach to explore
systemic immunological markers that can facilitate patient
selection and treatment decisions [14]. In particular, sev-
eral papers reported clinical significance of naïve/memory
T cell subsets as potential biomarkers with a prognostic
and/or predictive of response to immunotherapy potential,
in different cancer types, such as non-small cell lung can-
cer (NSCLC) [15] and melanoma [16, 17]. Four functional
T cell compartments can be defined in humans by the
expression of CC-chemokine receptor 7 (CCR7) and CD45RA:
naïve (N, CCR7+CD45RA+); central memory (CM, CCR7
+CD45RA−); effector memory (EM, CCR7−CD45RA−), and
terminally differentiated effector (TD, CCR7−CD45RA+) T
cells [18, 19].
In this study, we present results of a harmonisation across
laboratories belonging to the “Lazio Network for Transla-
tional Medicine and Tumour Biotherapies” of a six-colour
FCM panel, designed for the identification of naïve/memory
T cell subsets in human cryopreserved PBMCs (cPBMCs) or
WB samples. Our workflow has been conceived to address
the most effective issues contributing to intra- and intero-
perator variability and the impact of analysis centralisation
on global results, according to a scheme analogous to a pro-
ficiency testing program. To this aim, the ISS reference cen-
tre managed logistics and distributed cPBMC and fresh WB
samples, as well as reagents and SOPs, to thirteen operators
distributed in five centres. Each participant performed
experiments in replicates by his own equipment and sent
raw and locally analysed data to ISS, which evaluated vari-
ability of both local and central analyses as well as opera-
tor/laboratory performance. The whole process highlighted
critical aspects of a harmonisation process and emphasised
advantages of sharing dried reagents and detailed SOPs as
well as of centralising the preanalytical phase and data anal-
ysis. Overall, our data represent a real-life example of har-
monisation workflow to dissect and manage variability
related to FCM immune-monitoring assays, especially in
multicentre clinical studies.
2. Methods
2.1. Survey. As a working unit of the “Lazio regional network
for translational medicine” (Italy), we started our activity by
surveying clinical and research groups of Lazio region
involved in immunomonitoring. A questionnaire (supple-
mentary material (available here)) was distributed to explore
their expertise, equipment, and interest in joining a harmoni-
sation process for immunophenotyping of human leukocyte
subsets. Five institutions (8 different laboratories, for a total
number of 13 operators, including a reference operator,
ROP), from different fields and organizations, positively
answered to the survey and adhered to the project: ISS,
SUR, IRE, OPBG, and INMI. Each operator was assigned a
confidential ID (from Op_A to Op_M) only known by the
operator himself and by the ISS coordinator group. A com-
plete list of participants, instruments, and software is
reported in Table 1.
2.2. Instrument Characteristics. Seven different instruments
with compatible optical configuration (three flow cytometer
models: Beckman Coulter (BC, Miami, FL); Gallios™, Becton
Dickinson (BD, San Jose, CA); FACSCanto™ II; and BD
LSRFortessa™) were used (Table 1). All the instruments had
to fulfil minimum requirements such as to support two laser
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sources (488 and 633/640nm) and to undergo an internal
quality control of alignment (required), sensitivity, and linear-
ity (highly recommended). ISS BD FACSCanto™ I+ under-
went a fluidic system upgrade (therefore comparable to BD
FACSCanto™ II), and it was the only instrument of the project
maintained according to the GMP standard of quality assur-
ance; all other cytometers were dedicated to research use only.
All instruments were equipped with the manufacturer’s
default optical configuration and were calibrated by using
the BD FACSDiva™ Cytometer Setting and Tracking System
Beads, except BC Gallios (BC Flow-Check Fluorospheres and
Spherotech, Lake Forest, IL; Rainbow Calibration Particles, 8
peaks).
2.3. Experimental Workflow. The experimental design shown
in Figure 1 describes preanalytical and analytical phases.
2.3.1. Preanalytical Phase. The ISS main centre defined a naï-
ve/memory T cell panel, by selecting monoclonal antibody
clones and antibody-fluorochrome combinations, in accor-
dance with FCM panel design rules [20]. Each selected
monoclonal antibody in liquid formulation was previously
titrated to achieve the highest resolution index [21]. We
licensed the supplier for the production of customised dried
antibody tubes after a prevalidation test carried out on five
healthy cPBMC donors and a stability testing assay con-
ducted on a WB sample, in 8 replicates for each time point
(data not shown). The proposed staining cocktail was a six-
colour custom reagent, based on the backbone and drop-in
concept, composed by a mixture of five dried antibodies,
essential for naïve/memory identification [19] (CD4-FITC,
CCR7-PE, CD8-PeCy5.5, CD3-PeCy7, and CD45RA-APC),
produced by the DURAClone Technology (Beckman Coul-
ter, #B38658, Life Science Europe, Geneva, Swiss); the dried
mixture was integrated with a live/dead discriminator
(LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit, Thermo
Fisher Scientific, Waltham, MA) for (a) cPBMCs or with
CD45 APC-Cy7 (BioLegend, San Diego, CA) in liquid format
for (b) WB staining (Table 2).
Reagents and SOPs containing experimental procedures
and including guidelines for gating strategy were provided
to peripheral sites that stained in triplicate two blood sample
sets: (i) cPBMCs isolated from buffy coats (n = 3); (ii) WB
samples (n = 3). The number of replicates was chosen based
on previous reports [9]. For logistic reasons, buffy coat and
WB samples were drawn from different groups of healthy
donors, collected in two separate days (Figure 1(a)).
(i) cPBMC Isolation, Cryopreservation, and Delivery.
This phase was centralised to avoid variability related
to PBMC isolation and freezing procedures (detailed
in supplementary material). PBMCs were isolated
from three healthy donor buffy coats (named PBMC1,
PBMC2, and PBMC3) collected at the Policlinico
Umberto I blood bank that usually releases buffy coat
bags 24 hours after blood collection as a safety policy.
cPBMC samples (4 vials per donor), as well as DURA-
Clone tubes, single-colour DURAClone compensa-
tion tubes, and one stock of LIVE/DEAD Stain Kit,
were shipped to participating centres. cPBMC vials
were delivered in dry ice and stored in liquid nitrogen
upon arrival at peripheral sites.
(ii) WB Sample Collection and Delivery. Aliquots of WB
drawn by three healthy donors (named WB1, WB2,
and WB3), collected in sodium-EDTA Vacutainer
(BD) tubes, were sent to the participants within the
same day, along with DURAClone tubes, one set
of single-colour DURAClone tubes for compensa-
tion, and one stock of anti-CD45 APC-Cy7, and
were maintained at room temperature until stain-
ing (24 h later).
2.3.2. Analytical Phase. Each operator received reagents and
detailed instructions for instrument set-up, sample staining,
acquisition, and data analysis (Figure 1(b)), specified in com-
monly agreed SOPs (detailed in the supplementary material).
(i) cPBMC Thawing and Staining. The participants were
asked to determine viability after cell thawing by
means of trypan-blue exclusion cell count according
to the “cPBMC thawing and counting” SOP. After-
wards, cPBMCs were stained in three separate days
(three experimental rounds for each donor), at
weekly scheduled intervals, according to the “PBMC
staining, acquisition, and analysis” SOP.
(ii) WB Staining. Staining was performed in triplicate for
each donor 24 hours later from blood collection,
according to “WB staining, acquisition, and analysis”
SOP. Cells were fixed and acquired the day after.
Table 1: Participants, instruments, and software. Five centres, with a total of 13 operators (including the reference operator, ROP), using
seven different flow cytometers dedicated to research use (except GMP-maintained BD FACSCanto™ I at ISS, with a fluidic system
upgrade, comparable to a BD FACSCanto™ II), participated to the harmonisation panel. Three flow cytometer models with compatible
optical configuration (BC Gallios™, BD FACSCanto™ II, and BD LSRFortessa™) were used. The data generated were analysed by
operators at peripheral sites (local analysis) using their own analysis software (Kaluza, FlowJo, or FACSDiva). Central analysis at ISS was
performed by the ROP with Kaluza software on local raw data (acquired fcs files).
5 centres 13 operators 7 instruments 3 instrument models 2 acquisition software 3 analysis software
ISS
SUR
INMI
IRE
OPBG
12 + 1 ROP
1 FACSCanto I+ (GMP)
3 BD FACSCanto II
2 BD LSRFortessa
1 BC Gallios
BD FACSCanto II
BD LSRFortessa
BC Gallios
BC Kaluza
BD FACSDiva
BC Kaluza
BD Diva
TreeStar FlowJo
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2.3.3. Flow Cytometry Local and Central Analysis: Gating
Strategy. Gating hierarchy was included in both cPBMC
and WB staining SOPs. Exemplary gating strategy is shown
in Figure 2, which depicts sequential steps for selecting the
population of interest, up to the identification of naïve/mem-
ory T cell subsets. Briefly, for both cPBMC and WB samples,
PBMCs: 3 healthy donor buffy coats
OP01 OP02 OP… OP13 OP01 OP02 OP… OP13
PBMC isolation and cryopreservation
PBMCs WB
(b)
(a) Preanalytical phase (ISS central laboratory)
Custom panel design and validation
cPBMC aliquots, dried antibody mixture,
reagents, and SOPs,
shipped to:
Whole blood (WB) : 3 healthy donors
Blood drawn in EDTA vacutainer tubes
WB aliquots, dried antibody mixture,
reagents, and SOPs,
shipped to:
cPBMC thawing preanalytical phase
(all operators)
Analytical phase (all operators)
Staining, acquisition and analysis
3 replicates/donor
performed in 3 different days
(3 experimental rounds, weekly scheduled)
3 replicates/donor
performed the same day
(1 experimental round)
Local analysis: each operator carried out acquisition and analysis by its own flow cytometer and
analysis soware
Centralised analysis: central lab (ROP: reference operator at ISS) performed analysis by Kaluza
soware of all operator locally generated .fcs files
Statistical analysis by IBM-SPSS and R processors
Figure 1: Flowchart. Workflow of the multicentre harmonisation of a six-colour flow cytometry panel for naïve/memory T cell
immunomonitoring.
Table 2: Antibody specifications–naïve/memory panel. Antibody-fluorochrome conjugates for naïve/memory T cell phenotype panel. The
panel was composed of a backbone dried mixture of five antibodies (a+b) and the drop-in liquid markers: live/dead discriminator for
PBMC (a) and anti-CD45 APC-Cy7 for WB (b) samples.
Marker Fluorochrome Clone Sample Supplier Format
a+b
CD4 FITC 13B8.2 PBMC/WB
Beckman Coulter
DURAClone custom
backbone (dried)
CCR7 (CD197) PE G043H7 PBMC/WB
CD8 PeCy5.5 B9.11 PBMC/WB
CD3 PeCy7 UCHT-1 PBMC/WB
CD45RA APC 2H4 PBMC/WB
a Dead exclusion marker Near-IR (NiR)
Live/dead
Fixable dead cell stain kit
PBMCs Thermo Fisher Drop-in (liquid)
b CD45 APC-Cy7 2D1 WB BioLegend Drop-in (liquid)
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we first selected the window of instrumental stable acquisi-
tion time lapse and singlet events. Lymphocytes were then
gated within live cells for cPBMCs (Figure 2(a)) or within
the CD45+ leukocyte region for WB (Figure 2(b)), and CD3
+ cells were subsequently identified within the lymphocyte
gate. Furthermore, participants were asked to draw a CD4
vs. CD8 expression plot, within CD3+ T cells, to gate single-
positive events, excluding CD4+CD8+ double-positive T cells,
which represent a functionally distinct cell subset with peculiar
behaviour, as described in several infectious and oncologic dis-
eases [22, 23]. Cells were further distinguished in naïve/-
memory subsets through the CD45RA/CCR7 combination
(Figure 2(c)), in CD3+, CD4+, and CD8+ events. Concern-
ing FCM analysis, the guidelines recommended to properly
adjust biexponential scaling to better visualise a specific cell
population [24]. Data sets underwent two different postac-
quisition analyses: (i) in the local analysis, each participant
individually applied compensation and gating strategies
using his/her own analysis software, reported percentages of
defined cell subsets on a shared register, and sent it back to
the ISS main centre (Supplementary Table S1); (ii) in the
central analysis, an expert flow cytometry “reference
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Figure 2: Gating strategy. Representative dot plots of cPBMC (a) and WB (b) samples: after selecting the window of instrumental stable
acquisition time lapse and singlet events, lymphocytes were gated within live cells (a) or CD45+ cells/leukocytes (b). CD3+ cells were
subsequently identified within the lymphocyte gate (common gate for (a) and (b) analyses) and further distinguished in CD4+ and CD8+
lymphocytes. After that, naïve/memory subsets were identified within CD3+, CD4+, and CD8+ T cells through CD45RA/CCR7
combination (c).
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operator” belonging to the ISS coordinating laboratory,
defined as ROP (Op_M), reanalysed all local raw fcs files
using Kaluza software.
2.3.4. Data Analysis. Data analysis was carried out using
IBM-SPSS V25 and R V3.6.1 software [25].
Operator performance was assessed by means of two dif-
ferent indicators:
(i) Z-Score. This indicator measured howmany standard
deviations a participant observation differs from that
of ROP. For each blood sample type, donor, and
parameter, the Z-score was calculated as Z = ðX – μÞ
/σ, where X is the operator observation (average of
donor-specific triplicate), μ is the average, and σ is
the standard deviation of n = 12 values measured by
ROP in a centralised analysis. Then, the median of
the donor-related values was calculated. We classified
the scores as follows: satisfactory if ∣Z‐score∣ < 2:0,
questionable if 2:0 ≤ ∣Z‐score∣ < 3:0, and unsatisfac-
tory if ∣Z‐score∣ ≥ 3
(ii) Coefficient of Variation (CV = SD/Mean). Intrao-
perator precision in specific parameter analysis is
shown as the median value of CVs estimated on each
donor triplicate. We generally considered acceptable
CV values below 0.20.
Interoperator variability was estimated by means of
(i) CV. This was calculated for each parameter as the
median of operator CVs, derived from the average
donor-triplicate values. Individual CV was used to
estimate repeatability in intra/interassay analysis of
each operator observations when evaluating a donor
sample in three replicates
(ii) Bias. This was estimated as an expression of operator
closeness to the reference value. The reference value,
determined as the average of the values obtained by
all the operators, centrally analysed by the ROP for
each parameter. For each participant, donor, param-
eter, and blood sample type, bias was assessed as the
difference between the average of triplicate values
measured by the participant and the reference value,
then divided by the reference value. The absolute
value of bias was then determined, and the median
value of operators’ bias for each parameter and
blood type is shown. For bias, we generally consid-
ered as acceptable values below 0.20
(iii) Intraclass Correlation (ICC). Data reproducibility
was determined for each cell subset as the agreement
among analysts in measuring the same subject. To
this aim, we used ICC, a statistical index indepen-
dent of marker population size that estimates the
ratio of biological (due to differences in donors) to
total variability, as previously described [26, 27],
and calculated in a 2-way design with “analyst” and
“donor” as random variables for each parameter,
considering the mean value of donor triplicates.
Acceptability threshold was defined by ICC > 0:75
Multivariate analysis was performed using PCA as imple-
mented in the built-in R function prcomp(), a dimension-
reduction tool that can be used to reduce a set of variables
to a smaller set that still contains most of the information,
as explained variance, in the original set. Data were first
centred and scaled for each donor and sample type. Parent
populations and subpopulation were analysed separately.
Biplots were drawn using the “ggbiplot” R package.
2.4. Ethical Issues. This study was coordinated by ISS (Rome,
Italy). All experimental protocols were approved by ISS and
all methods were carried out in accordance with the Declara-
tion of Helsinki and other relevant international guidelines
[28]. Blood samples were collected from healthy donors
enrolled at Policlinico Umberto I blood bank (Rome, Italy)
after obtaining their written informed consent.
3. Results
To harmonise our naïve/memory panel, we evaluated variabil-
ity of data sets obtained from thirteen experienced operators
working in five independent centres of the Lazio region, using
seven different instruments (three flow cytometers models)
equipped with compatible laser and detector/filter settings
and three different software of analysis (Table 1).
In two out of the five centres, multiple operators partici-
pated to the harmonisation panel, some of them working on
different flow cytometers and using different analysis soft-
ware. Therefore, hereafter, we will refer intra- and intero-
perator variability as expression of the contribution of each
operator independently from the centre. cPBMC replicates
were obtained in different experimental rounds (interassay
replicates), whereas WB replicates were carried out within
the same day (intra-assay), as previously stated.
3.1. cPBMC Recovery and Viability. Results on recovery and
viability of cPBMCs after thawing revealed that this experi-
mental phase was not subjected to large variability among
operators as most of them (10/13) showed a coefficient of
variation (CV) between 0.06 and 0.20 for the recovery index
and 12/13 showed CV value below 0.11 for the viability index
(Supplementary Fig. S1a and b). Regarding WB, six of the
total processed samples (n = 117) were excluded from the
graphic and statistical analysis (outliers) due to problems
related to red blood cell lysis and other artefacts, as reported
by participants.
3.2. Distribution of T Cell Populations.We compared local vs.
centralised analysis of all T cell subset frequencies by mean of
boxes representing triplicate mean values obtained in all
observations (n = 12), from one representative donor for
cPBMC (upper box-plot panel) and one for WB samples
(lower box-plot panel, Figure 3). In yellow boxes, percentages
obtained by ROP are reported.
As expected, major CD3+ (gated within lymphocytes;
Figure 3(a)), CD4+, and CD8+ (gated within CD3+ cells;
Figure 3(b)) populations showed a very limited
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dispersion of frequencies if compared to naïve/memory
subsets (Figures 3(c)–3(e)), especially in the central analysis.
Dispersion of frequency profiles was far more evident in
locally analysed WB as compared to cPBMC samples.
However, centralisation reduced it to a greater extent in
WB setting.
Of note, regarding cPBMC plots, we found a CD4/CD8
ratio lower than the normal expected value and a very high
percentage of TD CD8 T cells with a consequently altered rel-
ative proportion of the other memory subsets (Figure 3(b)).
ROP results (yellow boxes) were mostly comparable to all
operator median values.
3.3. Intraoperator Variability/Operator Performance. The
number of participants was suitable to assess operator consis-
tency to SOP through a proficiency testing-like approach.
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To address the performance of all participants, we
evaluated intraoperator repeatability (i.e., variability of
individual measurements on the same donor, expressed
as CV in Supplementary Fig. S2), as well as standardised
residuals (i.e., Z-score; Figure 4) [29], on both cPBMC
and WB specimens, for each analysed parameter.
Concerning repeatability, interassay analysis in cPBMC
globally revealed a maximum CV value of 1.32 vs. 0.75 and
median CV values of 0.13 vs. 0.14 in local vs. central results
(Supplementary Fig. S2a and S2b). However, in this setting,
CVs for many of the parameters are often laid above the
acceptability threshold (52/195 and 56/195, by local and
central analysis, respectively). Of note, for some operators,
such as Op_G, centralisation reduced the CV values up to
levels that indeed were still not acceptable (Supplementary
Fig. S2a and S2b and Figures 4(a) and 4(b)). On the other
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Figure 4: Operator performance. Z-score measured how much the operators overestimate (red) or underestimate (blue) the values with
respect to an average reference value (average of the values obtained from all the operators centrally analysed by the ROP). Heat maps
represent a detailed study of concordance with the average reference results, relative to each separate parameter for cPBMC (a, b) and WB
(c, d) locally (a, c) and centrally (b, d) analysed.
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hand, in WB intra-assay analysis, CV values were excellent
(by far below 0.20) for almost all operators (only 5/195
and 2/195 above the 0.20 threshold), with maximum CV
values of 0.28 and 0.29, respectively, and a median CV
value of 0.03 for both local and central analyses (Supple-
mentary Fig. S2c and S2d). The lower operator precision
observed in cPBMCs in terms of CV can be mainly ascrib-
able to the complex preanalytical phase in this setting
(thawing).
In central analysis, Z-score was never found unsatisfac-
tory (Figures 4(b) and 4(d)), while in local analysis, some
parameters were under- or overestimated, slightly in
cPBMC (1/195) and notably in WB (49/195) setting
(Figures 4(a) and 4(c), respectively). Therefore, we can
argue that centralisation marginally influenced operator
performance in cPBMCs, while it considerably impacted on
WB setting, suggesting that local WB variability, for certain
operators, was mostly affected by analysis type, rather than
staining and acquisition phase.
Of note, ex post analysis of reference operator (ROP: Op_
M) performance revealed that this operator reached one of
the best scores among all operators.
3.4. Interoperator Variability/Subpopulation Reliability. In
order to address the impact of analysis type (centralised vs.
local) on overall interoperator measurement uncertainty,
we evaluated each parameter on both the cPBMC and WB
sets of experiments: (a) reproducibility expressed as CV, (b)
bias calculated with respect to the reference value, and (c)
agreement by means of ICC (Figure 5).
In Figure 5(a), bars represent median values among the
three donor-specific CVs (obtained on the three replicates
for each cPBMC (n = 3) and each WB (n = 3) specimen. As
expected [30], the median CV was lower for abundant popu-
lations (i.e., CD3+ cells within lymphocytes, and CD4+ or
CD8+ cells within CD3+ T cells), and higher for less-
represented and poorly resolved subsets, such as CD4+ TD
cells. In particular, acceptable precision values (CV below
0.20) were obtained for 8/15 vs. 12/15 parameters in cPBMC
and for 6/15 vs. 13/15 parameters in WB experiments, in
local vs. centralised analysis, respectively.
Regarding bias, mean values below 0.20 (considered
acceptable) were achieved for 9/15 vs. 13/15 in cPBMCs
and 7/15 vs. 14/15 parameters inWB locally vs. centrally ana-
lysed samples (Figure 5(b)).
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Figure 5: Interoperator variability. Overall interoperator variability related to the identification of CD3, CD4, and CD8major subpopulations
and naïve/memory T cell subsets, by all operators, in cPBMC (upper panel) and WB (lower panel) samples. Interoperator variance was
expressed as (a) CV calculated as the median of analyst-specific CV, derived from the three average donor triplicates for each marker; (b)
bias, calculated with respect to the mean reference value (average of the values obtained from all the operator data centrally analysed by
the ROP); and (c) ICC, as an index of reproducibility, calculated in a 2-way design with “analyst” and “donor” as random variables for
each parameter, considering the mean value of donor triplicates. CV, bias, and ICC among sites are shown for local (red bar) and
centralised (blue bar) data analyses.
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Agreement among observations produced by operators
when evaluating each cell subset was expressed as ICC, a sta-
tistical method independent of population size that estimates
the ratio of biological to total variability [26, 27] (Figure 5(c)).
For comparisons between groups, ICCs of 0.6–0.8 are consid-
ered adequate [31], while they should be >0.9 when taking
patient-specific decisions [32]. Here we assume that ICC
values above 0.75 were acceptable, as reported by other
authors [26]. ICC laid above the acceptability threshold for
5/15 vs. 7/15 in cPBMC and for 2/15 vs. 11/15 parameters
in WB samples, in local vs. centralised analysis.
We can point out that some subpopulations were subject
to more variability in cPBMC as compared to WB setting.
Specifically, the CD8-N subset proved to be out of the accept-
ability range for both accuracy (CV and Bias) and agreement
(ICC), thus turning out to be the less reliable parameter
under study. Other cPBMC subsets sensitive to variability
were CD3-EM (high CV value), CD3-TD, CD3-EM, CD8-
CM, and CD3-CM (low ICC value), as well. Finally, CD4+
cells were prone to low interoperator agreement, even though
they are a well-represented and identifiable subset; this find-
ing might be mainly ascribable to the cryopreservation han-
dling which contributes to the interassay uncertainty to
interdonor variability.
CD4-TD suffered from poor accuracy but displayed
acceptable agreement among operators in both WB and
cPBMC settings. On the other hand, in WB samples, CD4-
EM showed low reproducibility (low CV), while CD8-EM
and all of the CM subsets (CD3-, CD4-, and CD8-) displayed
low ICC.
Based on previously described operator’s performance
results (Supplementary Fig. S2 and Figure 4), we recalculated
the agreement by the ICC method on WB centrally analysed
data, selecting operators with Z-score values between -1.5
and 1.5 in Figure 4, thus excluding operators B, F, H, and
K. This selection improved operator concordance for most
parameters, even if 2 out of 15 (CD3-CM and CD4-CM) were
still below 0.75 thresholds (Supplementary Fig. S3).
3.5. Multivariate Analysis. Principal component analysis
(PCA) was used to explore whether observations of multiple
populations clustered according to three possible sources
of variability: centre, specific instrument, and instrument
model. To this aim, PCA was applied on WB centrally ana-
lysed data only, to exclude variability due to local gating
and compensation as well as the interassay uncertainty of
the cPBMC model (Figure 6).
In WB, the PCA analysis revealed that in parent popula-
tions (CD3+, CD4+, and CD8+; Figures 6(a)–6(c)), the first
two components accounted for 99.4% of total variance.
CD4 and CD8 almost entirely contribute to the first principal
component and were anticorrelated, as expected; the second
principal component primarily accounted for CD3 variabil-
ity. After clustering, data related to centre no. 5 (C5 in
Figure 6(d)) appeared more dispersed as compared to other
centres. Similarly, instrument no. 6 (I6 in Figure 6(e)) and
instrument model no. 2 (IM2 in Figure 6(f)) showed the
poorest performance. As a consequence, it was not feasible
to uniquely identify a possible source of variability among
those evaluated for major lymphocyte subpopulation.
On the other hand, PCA of naïve/memory cell subsets
(Figures 6(d)–6(f)) revealed that 63.9% of the variance was
represented in a 2-dimensional space. As a general rule, the
variables were grouped according to the naïve/memory sub-
population type rather than original (parent) population.
EM variables mostly contributed to the first component
and were negatively correlated to TD and N variables. CM
variables contributed mostly to the second component.
Operator observations showed to be grouped separately
along the first principal component according to the instru-
ment used for the acquisition, but neither to the centre oper-
ator’s work in nor to the instrument model. In particular,
instrument no. 4 (I4 in Figure 6(e), the green ellipse) is
apparently prone to an EM variable overestimation. Never-
theless, data obtained by two out of three operators using this
instrument did not show a higher variability compared to
others, so that we had no reasonable argument to exclude
instrument no. 4 from global analysis.
3.6. Instrument Sensitivity. To address instrument no. 4
behaviour, we compared each parameter fluorescence inten-
sity profiles derived from WB central analysis (Supplemen-
tary Fig. S4), within the indicated parent population,
selecting data produced by the most performant operator
for each instrument (as per Figure 4). As expected [33],
CCR7 and CD45RA profiles were characterised by a typical
pattern, with negativity and positivity peaks not neatly sepa-
rated; therefore, discrimination between positive and nega-
tive events could be easily biased. It is worth noting that
CCR7 was poorly resolved (2 channel decades of fluorescence
intensity by instrument no. 4 vs. 3 channel decades by most
of the instruments), causing greater difficulty in distinguish-
ing positive from negative events. No differences among
instruments were found for the comparing resolution index
[21] relative to each marker of the panel (data not shown).
Graphical study of bidimensional plots, built on the
CCR7/CD45RA expression in CD3+ cells, confirmed that
poorly resolved parameters could generate difficult position-
ing of negativity/positivity quadrants (Supplementary Fig. S5).
4. Discussion
Multicolour flow cytometry is a powerful tool for phenotyp-
ical and functional characterisation of immune cell subpop-
ulations; however, the use of this technique in multicentre
clinical trials has historically been limited by complexity,
costs, and inconsistent methods for sample handling,
reagents, instrument set-up, and data analysis among labo-
ratories. So far, many international initiatives have sup-
ported programs for the harmonisation of flow cytometry
methods [11–13, 34].
Here, we present a FCM harmonisation workflow
directed by ISS among laboratories belonging to the immu-
nomonitoring working group of the Lazio regional network
for translational medicine, based on a previously described
“mixed model” [35], to simulate a real multicentre study,
where an operator’s individual capacity in sample handling,
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Figure 6: Multivariate analysis by PCA. Biplots displaying both operators’ readings (points) and parameters (vectors). Confidence ellipses are
provided (CI = 95%) for operators’ readings after grouping them according to “Centre” (a, d), specific “Instrument” (b, e), and “Instrument
model” (c, f) to analyse the impact of such factors on major (a–c) and naïve/memory (d–f) lymphocyte subsets. Ellipses can be drawn when at
least 3 readings are available in groups. Results from one representative WB donor are shown.
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processing, and analysis by his/her own instrumentation and
software are maintained. This approach primarily constitutes
a concrete tool to evaluate reproducibility of data as well as to
identify and stem obstacles related to critical elements affect-
ing variability in FCM assays.
Although in recent years a considerable amount of com-
plex panels with an increasing number of parameters has
been developed, we defined a basic panel, compliant with
equipment of involved laboratories, identifying circulating
naïve/memory T lymphocytes that represent clinically rele-
vant cellular populations in different cancer immunotherapy
settings [18, 19].
As a versatile tool to be used in both cPBMC andWB set-
tings, we designed a backbone reagent consisting of a dried
mixture of five antibodies essential to detect naïve/memory
lymphocyte subsets.
Similar dried antibody mixtures have already proven to
yield high-data reproducibility and reliability in large-scale
projects such as the ONE study [13], the PreciseADS study
[34], and others [35–37]. These reagents contain exactly the
same amount of dried antibodies precoated in individual
tubes for direct labelling of cells from the same batch and
are very stable overtime, offering the advantage of speeding
up and simplifying the labelling procedure, reducing the num-
ber of technical steps, and avoiding the maximum of biases.
Despite computational automated methods having
reached a sufficient level of maturity and accuracy for reliable
use in flow cytometry, in this study, we focused on manual
analysis, since most centres are not equipped with bioinfor-
matics resources and expertise. It is well known that manual
gating [38] is a critical issue in FCM immunomonitoring
assays. For this reason, we wanted to estimate to what extent
analysis centralisation could amend local variability. To this
aim, raw acquisition files were centrally reanalysed by an
expert reference operator at ISS (ROP), who showed ex post
one of the best accuracy score among participants.
We finally generated two independent data sets for
cPBMC and WB samples, considering that both biological
matrices might offer advantages and disadvantages in the
context of clinical studies.
In this regard, the use of cPBMCs facilitates management
and shipment costs, enabling simultaneous retrospective
analysis of samples, collected from the same patient at differ-
ent time points. However, PBMC isolation and cell freezing
are not always feasible in all centres. In addition cryopreser-
vation procedures as well as the use 24-hour-old buffy coat
might lead to some artefacts and importantly modify the
ex vivo immune cell composition [26, 39, 40], even though
a resting time lapse might restore frequencies of some cell
populations [41]. In fact, when taking into account central
analysed data only, cPBMCs showed a TD cell increase as
well as alterations of other subset frequencies [39, 40].
On the other hand, fresh whole blood does not require
complex preanalytic phases and more accurately reflects the
ex vivo cellular composition, enabling the detection of gran-
ulocytes otherwise excluded by the Ficoll density separation.
Despite a preliminary stability test having confirmed that
delayed staining and acquisition of WB samples may gener-
ate artefacts in some population frequency evaluation [12],
we set up WB staining 24 hours after blood withdrawn and
sample acquisition on the following day. This procedure
allowed simulating a realistic sample management in a multi-
centre study [42, 43] and also fulfilled specific needs of some
involved laboratories. Several reports used blood stabilisers
in order to delay sample staining and acquisition, with differ-
ent outcomes depending on analysed markers [44]. However,
we considered these reagents not suitable for interassay vari-
ability testing of naïve/memory subpopulations since, in our
experience, CCR7 can be downregulated.
Concerning operator performance, in locally analysed
cPBMCs, each participant displayed an adequate concor-
dance with reference median values while, for some of them,
precision values were found out of acceptability range in naï-
ve/memory subsets and analysis centralisation could just
mitigate but not abolish this trend, as also observed in inter-
operator analysis.
In WB, some operators displayed high repeatability
but failed to analyse samples in terms of concordance for
many parameters, including CD3, CD4, and CD8. This vari-
ability might be ascribable most likely to improper individual
interpretation of the SOP relative to T cell gating, probably
due to the fact that WB is less employed for immunopheno-
typing among participating laboratories with respect to
PBMC samples.
Regarding subset reliability, data variability in both cellu-
lar models was very limited for large lymphocyte subpopula-
tions as expected, while it was wider for some naïve/memory
cell subsets. In fact, these populations are defined by the bidi-
mensional expression of CCR7 and CD45RA, two markers
characterised by continuous and poorly resolvable expres-
sion profiles, which require to be processed by high-
resolution cytometers. Distinctively, CD4-TD cells showed
the worst CV and bias values both in the interoperator study
of variability and in the intraoperator analysis of precision,
while their agreement among operators was acceptable in
both cPBMC and WB settings. These findings were not sur-
prising since CD4-TD showed very low percentages (nearby
zero) and CV and bias are influenced by the arithmetic mean,
while ICC index is not. For this reason, when evaluating a
FCM assay variability, we recommend to calculate all of the
described indexes and parameters, since they can reflect dif-
ferent features related to it.
In the WB setting, most participants revealed good
trueness and good agreement. Nevertheless, some correc-
tive measures are still required to reach a complete control
of reproducibility for our panel, since few memory subsets
persisted out of the acceptability range even after selecting
the best performant operator centrally analysed data.
Overall results confirmed that WB should be preferred to
cPBMCs if centrally analysed, for two main reasons: (i) it is
less affected by variability [13] and (ii) it more truthfully
reflects ex vivo peripheral leukocyte composition [41]. How-
ever, we should remind that we cannot make direct compar-
ison, because distinct donors were used in the two settings
and because we are dealing with interassay replicates for
cPBMC and intra-assay replicates for WB.
In addition, our data demonstrated that the major impact
of variability is due to operator intervention, while we had
12 Journal of Immunology Research
evidence that instrument models and respective configura-
tions did not influence variability in a great extent. Thus,
we confirmed that in studies involving multiple laboratories,
it would be practicable to operate on different brands [45]
and types of cytometers, as long as they are maintained under
high-quality standard to avoid misleading results.
5. Conclusion
The present study shows that our approach based on shared
protocols, centralised FCM data analysis, and extensive sta-
tistical analysis allows to identify variability sources and to
achieve well-harmonised and reproducible results in the
WB setting, overcoming assay variability among operators.
We highlighted that the main factors affecting variability
are represented by the individual conformity to SOPs related
to sample handling and gating procedures. In fact, precise
gating is a key prerequisite of reliable data and centralisation
of FCM analysis enabled to reach reproducible results, thus
allowing to bypass local analysis variability. Moreover, some
corrective measures, such as more detailed SOPs for PBMC
thawing and WB red blood lysing procedures, are still
required in order to optimise reproducibility and consistency
among different laboratories. Improved procedures are
needed as well to detect improper sensitivity among different
cytometers [46].
Finally, our results demonstrated that the proposed panel
is suitable for immunomonitoring of peripheral blood naï-
ve/memory T cells in multicentre clinical trials, provided that
instruments employed pass the proper quality check and
operators are well trained and coordinated.
In general, a tuning phase, by means of a proficiency
testing approach, should be carried out before starting
any multicentre immunomonitoring among participating
laboratories. Controlling and correcting for technical vari-
ability will enable the dissection of true biological variation
among subjects, thus allowing the identification of possible
immune biomarkers, either prognostic or predictive of
response to therapy, that will help personalised therapeutic
choice [47].
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Supplementary Materials
Supplementary Figure S1: (a) recovery and (b) viability of
PBMCs after thawing. Data are shown for each of the three
aliquots of each donor (PBMC1, PBMC2, and PBMC3)
thawed in 3 different rounds by each operator (Op_A to
Op_M). (a) The percentage of cells recovered regardless
of viability (cell count after thawing/cell count before
freezing); (b) the percentage of viable cells recovered (live
cells/total counted cells after thawing) by each operator.
Individual and median operator CVs are shown for both
recovery and viability indices. Supplementary Figure S2:
intraoperator variability. Interassay repeatability of each
operator for each cell subset for PBMCs after local and
central analysis ((a) and (b), respectively). In this case,
CV was first calculated for each donor-specific triplicate
(3 rounds) and then the median value was determined
on the 3 donors. Intra-assay repeatability of each operator
for each parameter for WB samples after local (c) or cen-
tralised (d) analysis. Here, the CV was calculated on the
three experimental replicas (1 round), and then the
median on the 3 donors was calculated. Centralisation
mitigated interassay variability for some cPBMC data,
while it did not affect WB intra-assay variability, which
was already excellent in the local analysis. Supplementary
Figure S3: agreement among selected best performant
operators. ICC values of WB centrally analysed data
obtained excluding 4 operators that showed Z-score above
1.5 or below -1.5 in Figure 4(d). Supplementary Figure S4:
fluorescence comparison among cytometers (1 Gallios
Beckman Coulter, 4 BD FACSCanto, and 2 BD LSRFor-
tessa). Data are shown from a representative WB sample.
Analysis was performed at the central site using Kaluza soft-
ware. Data are represented as fluorescence histograms for
each parameter within the gated cells (CD45 within the sin-
glet gate, CD3+ cells within the lymphocyte gate, and CD4
+, CD8+ CD45RA, and CCR7+ cells within CD3+ gated
cells). Supplementary Figure S5: CCR7-CD45RA bidimen-
sional plots. Comparison among operators. Data are shown
from a representative WB sample. Analysis was performed
at the central site using Kaluza software. Data are represented
as fluorescence plots within CD3+ cells. Supplementary
Table S1: data report form. Participants were asked to fill
the present form with their local analysis results for (a)
cPBMCs and (b) WB samples. Survey questionnaire. Stan-
dard operating procedures (SOPs): (i) PBMC isolation and
freezing; (ii) PBMC thawing and counting; (iii) PBMC stain-
ing, acquisition, and analysis; and (iv) WB staining, acquisi-
tion, and analysis. (Supplementary Materials)
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